Janssen COVID-19 vaccine approved for use in EU on March 11
Created on:
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
Janssen first approached the LUMC Molecular Virology group in February of 2020. “A collaboration to support the development of the Janssen COVID-19 vaccine was proposed because they knew we had been studying coronaviruses for over 30 years”, says Professor Eric Snijder of the LUMC department of Medical Microbiology. Together, Snijder and Dr Marjolein Kikkert were responsible for leading the project. Snijder emphasizes that they were able to rapidly assist with the first phase of vaccine development and testing due to LUMC’s well-established research infrastructure: “not only did we have the experience, but we also had trained staff available and a state-of-the-art Biosafety Level 3 (BSL-3) laboratory”.
More news & updates
Dr. Jeremia J. Pyuza: From Scientific Collaboration to Community Impact in Tanzania
In the third edition of our “Faces Behind LUMC Global” interview series Dr. Jeremia J. Pyuza, a medical doctor and laboratory scientist, tells us the inspiring story of his journey from Tanzania to the Netherlands. Through his passion for research, he is committed to making an impact within rural and urban communities of his home country Tanzania.
Jogchum Beltman: From Tropical Doctor in Malawi to Gynecologist-Oncologist in Leiden
In the fourth edition in our “Faces Behind LUMC Global” series, Dr. Jogchum Beltman, a gynecologist-oncologist at LUMC brings us back to the early days of his career as a tropical doctor in Malawi and his current work as a medical specialist. A story about his experiences and the challenges he faced in this exciting field.
Indonesian Fathimah Sigit obtains her PhD for international research on obesity and metabolic syndrome
Global epidemics come in many forms and attract different kinds of attention depending on the severity of the diseases. But as Fathimah’s research demonstrates, there’s a risk that comes with giving too little attention to epidemics that don’t have immediate life altering/threatening effects. It’s for this exact reason that obesity is often overlooked in terms of severity. In the short term, obesity isn’t life threatening perse, but over time, the complications of obesity become progressively more dangerous and ultimately life threatening. With around 40 percent of the global population being overweight and 13 percent suffering from obesity, Fathimah’s recent PhD research on the topic might prove invaluable in the future.